- Trials with a EudraCT protocol (89)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
89 result(s) found for: Matched placebo.
Displaying page 1 of 5.
EudraCT Number: 2009-011044-20 | Sponsor Protocol Number: D1710C00006 | Start Date*: 2009-04-08 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Single-Centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four Period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600mg and 150mg) on QT/QTc Interval, C... | |||||||||||||
Medical condition: rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004131-23 | Sponsor Protocol Number: GA1212 | Start Date*: 2013-01-18 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd | ||
Full Title: A single-centre, randomised, 2 way crossover, double blind, placebo controlled study in healthy volunteers, to characterise the antacid activity of Gaviscon Double Action Mint Liquid in the fasted ... | ||
Medical condition: This study is to demonstrate the antacid action of Gaviscon Double Action Mint versus a matched placebo using a pH catheter. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-002839-24 | Sponsor Protocol Number: 108134 | Start Date*: 2006-08-18 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A randomized, double-blind, placebo-controlled, multi-country and multi-center, phase IV study to demonstrate the efficacy of GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscula... | ||
Medical condition: Immunization against influenza in male and female subjects aged 18 to 64 years | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-021630-63 | Sponsor Protocol Number: GA1001 | Start Date*: 2011-03-28 |
Sponsor Name:Reckitt Benckiser | ||
Full Title: A randomised, double blind placebo controlled study in patients with reflux symptoms to assess suppression of gastro-oesophageal reflux by ‘Gaviscon Double Action Peppermint liquid’ using the BRAVO... | ||
Medical condition: Gastro-oesophageal reflux disease (GORD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-000572-15 | Sponsor Protocol Number: EGF117268 | Start Date*: 2013-07-01 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: Investigation of immune mechanisms relating to lapatinib associated hepatotoxicity: ex vivo T cell biology investigation relating to lapatinib induced liver adverse events using PBMCs from patie... | ||
Medical condition: The subjects participated in the EGF105485 study, a randomized, placebo-controlled study of lapatinib in HER2-positive early-stage breast cancer. During participation in this study, subjects had b... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DK (Completed) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005261-69 | Sponsor Protocol Number: GA1402 | Start Date*: 2015-08-06 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited | ||
Full Title: A multi-centre, randomised, double-blind, two arm, parallel group, placebo-controlled study to assess the effect of Sodium Alginate Chewable Tablets on symptoms of gastro-oesophageal reflux disease. | ||
Medical condition: Gastro-Oesophageal Reflux Disease (GORD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-003179-33 | Sponsor Protocol Number: BV-2021/06 | Start Date*: 2021-11-29 | |||||||||||
Sponsor Name:OM Pharma SA | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-controlled, 32-week, Phase IIa trial to investigate the efficacy of OM-85 versus matched placebo in reducing disease severity in children aged 3 to 24 months wit... | |||||||||||||
Medical condition: Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003202-16 | Sponsor Protocol Number: PB/0046 | Start Date*: 2015-10-20 |
Sponsor Name:Academic Medical Centre | ||
Full Title: A randomized, double-blind, placebo-controlled study to compare the safety and immune effects of multiple doses of vitamin D3 in patients with allergic rhinitis/rhino-conjunctivitis caused by birc... | ||
Medical condition: subcutaneous immunotherapy in allergic rhinits (AR) patients with allergies to birchpollen | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002214-47 | Sponsor Protocol Number: KIT-302-03-02 | Start Date*: 2016-10-04 | |||||||||||
Sponsor Name:Kitov Pharmaceuticals Ltd | |||||||||||||
Full Title: A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine on Renal and Vascular Function in Subjects with Existing Hypertension ... | |||||||||||||
Medical condition: Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003174-17 | Sponsor Protocol Number: GA1405 | Start Date*: 2015-03-24 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited | ||
Full Title: A multicentre, randomised, double-blind, two arm, parallel group, placebo controlled pivotal study to assess the effect of a sodium alginate liquid suspension as add-on therapy in GORD patients wit... | ||
Medical condition: Gastro-Oesophageal Reflux Disease (GORD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001502-15 | Sponsor Protocol Number: 2016-01382 | Start Date*: 2017-12-13 | |||||||||||
Sponsor Name:Insel Gruppe AG - Inselspital | |||||||||||||
Full Title: Effects of the PCSK9 Antibody AliroCuMab on Coronary Atherosclerosis in PatieNts with Acute Myocardial Infarction. A Serial, Multivessel, Intravascular Ultrasound, Near-Infrared Spectroscopy And Op... | |||||||||||||
Medical condition: Patients presenting with acute myocardial infarction (non-ST-elevation myocardial infarction or acute ST-elevation myocardial infarction) and with elevated cholesterol levels. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005494-11 | Sponsor Protocol Number: VERI-LONG | Start Date*: 2023-03-14 | |||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: A parallel-group treatment, phase 2a, double-blind, placebo-controlled 2-arm study to show improvement of physical function in SF-36 (SF-36-PF) in participants treated with Vericiguat compared to p... | |||||||||||||
Medical condition: Post-COVID-19 syndrome without (PCS) or with (PCS/CFS) fulfillment of myalgic encephalomyelitis/chronic fatique syndrome (ME/CFS) criteria | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003236-37 | Sponsor Protocol Number: 20160184 | Start Date*: 2018-11-02 | ||||||||||||||||
Sponsor Name:Amgen Inc. | ||||||||||||||||||
Full Title: High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS) | ||||||||||||||||||
Medical condition: Dyslipidemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) HU (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-003634-15 | Sponsor Protocol Number: CQAB149B2211 | Start Date*: 2006-09-13 | |||||||||||
Sponsor Name:NovartisPharma Services AG | |||||||||||||
Full Title: An exploratory, double-blind comparison of inspiratory capacity (IC) and FEV1 in COPD patients following single dose administration of indacaterol and placebo and open-label b.i.d. administration o... | |||||||||||||
Medical condition: Mild to severe COPD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001239-38 | Sponsor Protocol Number: CP-PRO-QVLP-012 | Start Date*: 2017-10-23 | |||||||||||
Sponsor Name:Medicago R&D Inc. | |||||||||||||
Full Title: A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64... | |||||||||||||
Medical condition: Seasonal influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002017-28 | Sponsor Protocol Number: LinaclotideRectumColon | Start Date*: 2014-07-16 |
Sponsor Name:KULEUVEN | ||
Full Title: ROLE OF THE TYPE AND SITE OF DISTENSION IN THE EVALUATION OF DRUGS EFFICACY IN MODULATING THE SENSORY AND MOTOR RESPONSE OF THE DESCENDING COLON AND THE RECTUM IN MAN | ||
Medical condition: HEALTHY SUBJECTS AND PATIENTS WITH IRRITABLE BOWEL SYNDROME | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004599-20 | Sponsor Protocol Number: PHRCN_2018_BACHOUMAS | Start Date*: 2021-07-27 |
Sponsor Name:CHU DE CLERMONT-FERRAND | ||
Full Title: Effects of early testosterone gel administration on physical performance in the critically ill: a randomised double blind clinical trial | ||
Medical condition: Patients receiving invasive mechanical ventilation and treatment with a vasoactive drug within 96 hours of ICU admission will be screened. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001219-31 | Sponsor Protocol Number: CLAF237A2387 | Start Date*: 2006-09-20 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on the incretin effect in patients with type 2 diabetes treated with metformin | ||
Medical condition: Type II Diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004109-27 | Sponsor Protocol Number: 2.12.05 | Start Date*: 2006-03-24 |
Sponsor Name:Neuropsychiatric clinic | ||
Full Title: A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies | ||
Medical condition: Parkinsons disease (PD)and dementia with Lewy bodies (DLB) are both common disease of the elderly. The majority of patients who survive for more than 10 years with PD eventually develope dementia ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011098-34 | Sponsor Protocol Number: CR081101/CO14950 | Start Date*: 2009-10-30 | |||||||||||
Sponsor Name:JSW Lifesciences GmbH | |||||||||||||
Full Title: A multicentre double-blind, placebo-controlled, randomised, parallel-group study to evaluate the efficacy and safety of Lornoxicam in patients with mild to moderate probable Alzheimer’s Disease. | |||||||||||||
Medical condition: Alzheimer's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
